Genmab (GMAB) is maintaining its 2025 financial guidance published on February 12, 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Executes Share Buy-back Transactions in Early May 2025
- Genmab to Submit sBLA for Epcoritamab Combination in Follicular Lymphoma
- Genmab Continues Share Buy-back Program in April 2025
- Genmab price target lowered to DKK 1,990 from DKK 2,970 at HSBC
- Genmab’s Strong Market Position and Growth Potential Justifies Buy Rating